company background image
600332 logo

Guangzhou Baiyunshan Pharmaceutical Holdings SHSE:600332 Stock Report

Last Price

CN¥28.87

Market Cap

CN¥44.6b

7D

-4.4%

1Y

-6.9%

Updated

24 Mar, 2024

Data

Company Financials +

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

SHSE:600332 Stock Report

Market Cap: CN¥44.6b

600332 Stock Overview

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, together with its subsidiaries, engages in the research, development, manufacture, and sale of Chinese patent and Western medicines, chemical raw materials, natural and biological medicines, and intermediates of chemical raw materials in the People’s Republic of China and internationally.

600332 fundamental analysis
Snowflake Score
Valuation4/6
Future Growth1/6
Past Performance2/6
Financial Health5/6
Dividends5/6

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Guangzhou Baiyunshan Pharmaceutical Holdings
Historical stock prices
Current Share PriceHK$28.87
52 Week HighHK$37.09
52 Week LowHK$26.50
Beta0.68
1 Month Change-3.12%
3 Month Change1.91%
1 Year Change-6.93%
3 Year Change3.11%
5 Year Change-25.97%
Change since IPO96.39%

Recent News & Updates

Recent updates

Shareholder Returns

600332CN HealthcareCN Market
7D-4.4%-2.9%-0.03%
1Y-6.9%-28.9%-14.2%

Return vs Industry: 600332 exceeded the CN Healthcare industry which returned -28.9% over the past year.

Return vs Market: 600332 exceeded the CN Market which returned -14.2% over the past year.

Price Volatility

Is 600332's price volatile compared to industry and market?
600332 volatility
600332 Average Weekly Movement2.7%
Healthcare Industry Average Movement6.6%
Market Average Movement8.1%
10% most volatile stocks in CN Market11.3%
10% least volatile stocks in CN Market5.1%

Stable Share Price: 600332 has not had significant price volatility in the past 3 months.

Volatility Over Time: 600332's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199728,048Hong Lihttps://www.gybys.com.cn

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, together with its subsidiaries, engages in the research, development, manufacture, and sale of Chinese patent and Western medicines, chemical raw materials, natural and biological medicines, and intermediates of chemical raw materials in the People’s Republic of China and internationally. The company operates through four segments: Great Southern Medicine, Great Commerce, Great Health, and Great Medical Care. It is also involved in the wholesale, retail, sale, import, and export of Western and Chinese medicines, and medical devices; and research and development, production, and sale of beverages, food, healthcare products, and other products; and production and sale of pre-packaged food, dairy products, etc., as well as offers herbal tea, tablets, capsules, lozenges, Guiling jellies, etc. In addition, the company invests in health industry, such as medical services, health management, health care, elderly care, etc.; and provides business and advertising agency services.

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Fundamentals Summary

How do Guangzhou Baiyunshan Pharmaceutical Holdings's earnings and revenue compare to its market cap?
600332 fundamental statistics
Market capCN¥44.57b
Earnings (TTM)CN¥4.06b
Revenue (TTM)CN¥75.52b

7.3x

P/E Ratio

0.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
600332 income statement (TTM)
RevenueCN¥75.52b
Cost of RevenueCN¥61.37b
Gross ProfitCN¥14.14b
Other ExpensesCN¥10.09b
EarningsCN¥4.06b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)2.49
Gross Margin18.73%
Net Profit Margin5.37%
Debt/Equity Ratio30.4%

How did 600332 perform over the long term?

See historical performance and comparison

Dividends

4.1%

Current Dividend Yield

30%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.